¿POR QUÉ LUPKYNIS?

Un tratamiento que lo ayuda a asumir el desafío

LUPKYNIS está ayudando a transformar la forma en que se trata la nefritis lúpica

Ayuda a controlar la nefritis lúpica

Para las personas que toman LUPKYNIS^a, la probabilidad de tener su nefritis lúpica bajo control^b después de un año de tratamiento fue casi 3 veces mayor^c que para las personas que toman solamente micofenolato de mofetilo (MMF) y esteroides.

Se redujo la dosis de esteroides necesaria

En ensayos clínicos, LUPKYNIS ayudó a detener el ataque de nefritis lúpica con dosis bajas de esteroides.

Reduce las proteínas en la orina

En ensayos clínicos, LUPKYNIS ayudó a reducir la proteína en la orina (llamada proteinuria, un signo clave de actividad de la enfermedad) aproximadamente 2 veces más rápido^d que MMF y esteroides solos.

Las personas que tomaban LUPKYNIS vieron una reducción del 50 % de la proteinuria, en promedio, después de solo un mes.

Se estudió en diferentes razas y orígenes étnicos

LUPKYNIS se analizó en estudios clínicos en los que participaron más de 350 personas de diferentes razas y orígenes étnicos, incluido el 32,5 % que eran hispanos.

^aComo parte de un plan de tratamiento que incluía micofenolato de mofetilo y esteroides.

^bSe definió el control como la reducción de la proteína en la orina a ≤0.5 mg/mg, mientras ayudaba a mantener la función renal.

^cEl cociente de probabilidades fue de 2.7.

^dEn promedio después de seis meses de tratamiento en comparación con un año para los pacientes que solo toman MMF y esteroides.

Since starting on LUPKYNIS,
I slowly resumed
some of
my normal activities I had
done prior
to my diagnosis.
That was such a great thing.

—Suriya, started treatment
in 2021

Feel confident talking to your doctor about LUPKYNIS

Our downloadable doctor discussion guide can help make starting the conversation easier.

Download

IMPORTANT SAFETY INFORMATION

BOXED WARNING: MALIGNANCIES AND SERIOUS INFECTIONS

LUPKYNIS increases the risk of serious infections and malignancies that may result in hospitalization or death. See full Prescribing Information for complete BOXED WARNING.

CONTRAINDICATIONS

DO NOT use with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, clarithromycin).
DO NOT use LUPKYNIS if a patient has a history of serious hypersensitivity reactions, including anaphylaxis, to LUPKYNIS or any of its components.

WARNINGS AND PRECAUTIONS

Nephrotoxicity may occur. Monitor eGFR and adjust dose as needed.
Hypertension is common. Monitor blood pressure. May require antihypertensive therapy; watch for possibility of drug interactions with some antihypertensives.
Neurotoxicity: Monitor for neurologic symptoms including risk of posterior reversible encephalopathy syndrome (PRES).
Hyperkalemia: Monitor potassium, especially with concomitant agents associated with hyperkalemia.
QT Prolongation: Monitor ECG and electrolytes in high-risk patients.
Hypersensitivity Reactions (Including Anaphylaxis and Angioedema): Monitor and discontinue if reaction occurs.
Pure Red Cell Aplasia: Monitor and consider discontinuation if diagnosed.
Immunizations: Avoid live vaccines.
Lymphomas and Other Cancers: Immunosuppressants increase the risk of lymphomas and other cancers, especially of the skin. Monitor for skin changes and advise sun protection and avoidance of artificial UV light.

ADVERSE REACTIONS

The most common adverse reactions (≥3% and ≥2% against placebo) include decreased GFR, hypertension, diarrhea, headache, anemia, cough, urinary tract infection, abdominal pain upper, dyspepsia, alopecia, renal impairment, abdominal pain, mouth ulceration, fatigue, tremor, acute kidney injury, and decreased appetite. Nausea and vomiting have been reported during post-approval use.

SPECIFIC POPULATIONS

Pregnancy: Inform female patients of the potential risk to a fetus and to avoid use of LUPKYNIS during pregnancy.

These are not all the possible side effects of LUPKYNIS. For more information, ask your healthcare provider. You may report side effects to FDA at 1-800-FDA-1088. You may also report side effects to www.fda.gov/medwatch.

WHAT IS LUPKYNIS?

LUPKYNIS is a prescription medicine used with other medicines to treat adults with active lupus nephritis. LUPKYNIS should not be taken with a medicine called cyclophosphamide. Talk with your healthcare provider if you are not sure if you take this medicine.

Please see full Prescribing Information, including BOXED WARNING, and Medication Guide for additional Important Safety Information about LUPKYNIS.